[1] World Health Organization. World malaria report 2022. Geneva: WHO; 2022. https://www.who.int/publications/i/item/9789240064898.
[2] Xu JW, Deng DW, Wei C, Zhou XW, Li JX. Risk factors associated with malaria infection along China–Myanmar border: a case–control Study. Malar J 2022;21(1):288. https://doi.org/10.1186/s12936-022-04312-5CrossRef
[3] Liu H, Zhou YW, Deng Y, Lin ZR, Zhang CL, Chen QY, et al. Malaria from hyperendemicity to elimination along international borders in Yunnan, China during 2003‒2020: a case study. Infect Dis Poverty 2022;11(1):51. http://dx.doi.org/10.1186/s40249-022-00972-2.
[4] Xu JW, Lin ZR, Zhou YW, Lee R, Shen HM, Sun XD, et al. Intensive surveillance, rapid response and border collaboration for malaria elimination: China Yunnan’s ‘‘3+1’’ strategy. Malar J 2021;20(1):396. https://doi.org/10.1186/s12936-021-03931-8CrossRef
[5] Huang F, Zhang L, Xue JB, Zhou HN, Thi A, Zhang J, et al. From control to elimination: a spatial-temporal analysis of malaria along the China-Myanmar border. Infect Dis Poverty 2020;9(1):158. https://doi.org/10.1186/s40249-020-00777-1CrossRef
[6] Xu JW, Liu H, Yaw B, Nbwi HS. The health beliefs, dengue knowledge and control behaviors among internally displaced persons versus local residents in Kachin Special Region II, Myanmar. PLoS Negl Trop Dis 2020;14(6):e0008321. https://doi.org/10.1371/journal.pntd.0008321CrossRef
[7] Xu JW, Li Y, Yang HL, Zhang J, Zhang ZX, Yang YM, et al. Malaria control along China-Myanmar border during 2007-20013: an integratred impact evaluation. Infect Dis Poverty 2016;5(1):75. https://doi.org/10.1186/s40249-016-0171-4CrossRef
[8] Liu H, Xu JW, Bi Y. Malaria burden and treatment targets in Kachin Special Region II, Myanmar from 2008 to 2016: a retrospective analysis. PLoS One 2018;13(4):e0195032. https://doi.org/10.1371/journal.pone.0195032CrossRef
[9] Tian P, Sun XD, Duan KX, Xu YC, Zhou YW, Guo XR, et al. Investigation on mosquito species and Plasmodium sporozoite infection in Anopheles mosquitoes in Laiza city, Myanmar, 2018. Chin J Vector Biol Control 2023;34(3):412 − 6. https://doi.org/10.11853/j.issn.1003.8280.2023.03.022CrossRef
[10] Lin ZR, Yin SS, Yang J, Guo XR, Dong CL, Lin YK, et al. The public health response to an outbreak of border-spill malaria along China-Myanmar border. PLoS One 2022;17(12):e0275932. https://doi.org/10.1371/journal.pone.0275932CrossRef
[11] World Health Organization, Global Malaria Programme. Malaria elimination: a field manual for low and moderate endemic countries. Geneva: WHO; 2007. https://iris.who.int/handle/10665/43796.
[12] Liu H, Xu JW, Deng DW, Wang HY, Nie RH, Yin YJ, et al. Dihydroartemisinin-piperaquine efficacy in Plasmodium falciparum treatment and prevalence of drug-resistant molecular markers along China-Myanmar border in 2014–2023. J Glob Antimicrob Resist 2023;35:271 − 8. https://doi.org/10.1016/j.jgar.2023.10.001CrossRef
[13] Bureau for Endemic Disease control, Ministry of Health, China. Manual of malaria control. 2nd ed. Beijing: People’s Health Publisher. 1988. https://book.kongfz.com/206600/4417701381/. (In Chinese). 
[14] Liu H, Xu JW, Deng DW, Yaw B, Nbwi HS, Wei C, et al. Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial. Parasit Vectors 2024;17(1):28. https://doi.org/10.1186/s13071-023-06058-8CrossRef
[15] Taylor WR, Olupot-Olupot P, Onyamboko MA, Peerawaranun P, Weere W, Namayanja C, et al. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet Infect Dis 2023;23(4):471 − 83. https://doi.org/10.1016/S1473-3099(22)00658-2CrossRef